Omberacetam

Overview

Omberacetam is the International Nonproprietary Name (INN) assigned by the World Health Organization to the compound more commonly known as Noopept (GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester). This naming distinction is important for regulatory and pharmacological clarity: while "Noopept" originated as a brand name in Russia where the compound is approved as a nootropic pharmaceutical, "Omberacetam" serves as the standardized global nonproprietary designation. The compound was developed in 1996 by Professor Tatiana Gudasheva at the Zakusov Institute of Pharmacology, designed as a dipeptide analog of the endogenous neuropeptide cycloprolylglycine (cPG) that could replicate and exceed the cognitive-enhancing profile of piracetam at dramatically lower doses.

Omberacetam's mechanism of action is multifaceted and distinguishes it from classical racetams. After oral or sublingual administration, the compound crosses the blood-brain barrier via peptide transport systems and is metabolized to cycloprolylglycine, which modulates both AMPA and NMDA subtypes of glutamate receptors — enhancing excitatory neurotransmission and facilitating long-term potentiation (LTP) without excitotoxicity risk. The most pharmacologically significant effect is robust upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cerebral cortex, driving neuroplasticity, synaptogenesis, and neuronal survival pathways. Additional mechanisms include antioxidant neuroprotection (scavenging of reactive oxygen species, inhibition of calcium-mediated mitochondrial apoptosis), anti-inflammatory modulation of neuroinflammatory cascades, and enhancement of alpha-wave cortical activity associated with relaxed alertness. Clinical studies in patients with cognitive impairment of vascular and traumatic origin have demonstrated significant improvements in memory, attention, and overall cognitive function.

Omberacetam is typically dosed at 10–30 mg daily, representing approximately 1/100th to 1/200th of effective piracetam doses — a potency ratio that reflects both enhanced CNS bioavailability and more efficient receptor engagement. The compound has a short plasma half-life (~60 minutes), though its neurotrophic effects persist beyond the acute pharmacokinetic window. It is commonly stacked with choline sources such as alpha-GPC or CDP-choline to meet increased acetylcholine demand, and combined with complementary nootropics like aniracetam, lion's mane, or N-Acetyl Semax for multi-pathway cognitive enhancement. Side effects are rare at standard doses and may include headache, irritability, or insomnia with late-day dosing. Omberacetam remains approved in Russia and available as a research compound internationally.

Mechanism of Action

Omberacetam (Noopept's close structural analog, also known as GVS-111 in some literature, but specifically the pharmaceutical-grade formulation developed in Russia) functions as a cognitive enhancer through modulation of glutamatergic neurotransmission and neurotrophic factor expression. Its primary mechanism involves positive allosteric modulation of AMPA-type glutamate receptors, where it binds to the S1-S2 extracellular domain interface and slows receptor desensitization, thereby amplifying fast excitatory synaptic transmission in hippocampal and cortical circuits. Omberacetam also potentiates NMDA receptor responses through enhancement of glycine binding site efficacy, facilitating calcium-dependent signaling cascades essential for long-term potentiation (LTP) induction.

Following oral administration, omberacetam is rapidly absorbed and converted to the active metabolite cyclo-prolylglycine, which mediates much of its chronic neurotrophic activity. This metabolite stimulates expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) through CREB phosphorylation, promoting hippocampal neuroplasticity, dendritic spine formation, and synaptogenesis. Omberacetam enhances cholinergic transmission by increasing acetylcholine release in the prefrontal cortex and hippocampus, contributing to its pro-cognitive effects on attention and working memory. It also demonstrates significant neuroprotective properties by inhibiting calcium overload-induced mitochondrial dysfunction, preventing opening of the mitochondrial permeability transition pore (mPTP), and reducing caspase-3-dependent neuronal apoptosis.

Therapeutically, omberacetam is approved in Russia for cognitive disorders associated with organic brain pathology, including post-traumatic and cerebrovascular conditions. Its cognitive enhancement profile spans improvements in memory consolidation, recall, attention, and executive function at remarkably low doses (10-30 mg/day). Preclinical evidence supports neuroprotective efficacy in models of Alzheimer's disease (reducing amyloid-beta toxicity and tau phosphorylation), stroke (limiting infarct volume through anti-excitotoxic mechanisms), and traumatic brain injury. The combination of acute receptor modulation with chronic neurotrophic support provides a dual-action mechanism distinguishing it from first-generation racetams.

Reconstitution Calculator

Safety Profile

Side effects are generally mild and may include headaches, insomnia, irritability, and gastrointestinal discomfort. It is contraindicated in individuals with severe hepatic or renal impairment and during pregnancy or lactation. Omberacetam may enhance the effects of other nootropics and psychostimulants, so careful dose management is recommended.

Pharmacokinetic Profile